At a Glance Commentary
======================

Scientific Knowledge on the Subject
-----------------------------------

Although no medical therapy provides relief from the progressive disability of severe emphysema, improved lung function and survival has been seen with lung volume reduction surgery. However, eligibility for lung volume reduction surgery is contingent upon the patient's overall health status and pattern of emphysema and is only offered at a limited number of centers. Thus, there is substantial need for less invasive treatment options for severe emphysema.

What This Study Adds to the Field
---------------------------------

The Spiration Valve System (SVS) consists of a one-way valve that blocks inspired airflow to distal portions of the lung affected by disease. Treatment of severe heterogeneous emphysema with the SVS in medically optimized participants achieved significant improvements in FEV~1~, hyperinflation, target lobe volume, dyspnea, and quality of life measures compared with optimal medical management alone. SVS offers clinically relevant benefits to severely ill patients with emphysema. The current study refined objective methods for using quantitative computed tomography as a tool to assess target lobe emphysema characteristics and determine eligibility for bronchoscopic lung volume reduction therapy.

Chronic obstructive pulmonary disease (COPD) affects an estimated 16 million U.S. residents ([@bib1]) and is the fourth leading cause of death in the United States ([@bib2]). Emphysema alone affects 4.7 million U.S. residents and is associated with progressive physical activity limitations, dyspnea, and reduced quality of life (QoL) ([@bib3], [@bib4]).

Pharmacologic COPD treatments have limited benefit ([@bib5]). Inhaled therapies reduce annual decline in FEV~1~ more than placebo; however, observed declines have not been clinically relevant. Other guideline-recommended treatments include pulmonary rehabilitation (PR) and continuous oxygen therapy ([@bib6]), but no medical therapy provides relief from the progressive disability of severe emphysema ([@bib5]).

The National Emphysema Treatment Trial showed that lung volume reduction surgery (LVRS) improved survival compared with medical treatment in participants with upper-lobe emphysema and low exercise capacity, and also improved health status, dyspnea, exercise capacity, and lung function ([@bib7]). Although effective, most qualifying individuals (80%) are ineligible for LVRS, primarily due to the potential morbidity associated with surgery and the pattern of emphysema and severity of lung function ([@bib8], [@bib9]). Thus, there is a substantial need for less invasive treatment options for severe emphysema.

The Spiration Valve System (SVS; formerly known as the intrabronchial valve) consists of a one-way valve that blocks inspired airflow using a flexible umbrella design. This allows for bronchoscopic placement in selected airway regions and limits airflow to distal portions of the lung affected by emphysema. The SVS has been evaluated in prior clinical studies using a bilateral, partial occlusion treatment methodology ([@bib10], [@bib11]), which proved ineffective. However, Eberhardt and colleagues ([@bib12]) along with other subsequent studies ([@bib13], [@bib14]) showed that unilobar total occlusion may provide similar physiologic and clinical benefits to LVRS, including reduced hyperinflation, leading to improved lung function and clinical status, in a minimally invasive and potentially reversible manner ([@bib15]).

Previous studies using endobronchial valves to treat patients with hyperinflated emphysema have reported that absence of collateral ventilation is pivotal in achieving lobar atelectasis, the overall treatment goal of this therapy ([@bib13], [@bib16], [@bib17]). Collateral ventilation can be assessed using a balloon-tipped catheter placed bronchoscopically to measure flow and pressure distally in the targeted lobe ([@bib18]). Alternatively, structural integrity of the fissure(s) adjacent to the targeted lobe can be assessed by quantitative high-resolution computed tomography (HRCT), which also acts as a marker for collateral ventilation and aids in patient and lobe selection ([@bib19]). The EMPROVE trial represents the largest multicenter study using HRCT analysis of fissure integrity for patient selection and targeted lobar treatment.

The results of the current research have been published in the form of two abstracts presented at the American Thoracic Society ([@bib20]) and the European Respiratory Society ([@bib21]) meetings in 2018.

Methods
=======

The EMPROVE study was a prospective, open-label, randomized, controlled, multicenter trial to assess the safety and efficacy of the SVS procedure in participants with severe heterogeneous emphysema.

Participant Population
----------------------

Up to 220 participants were to be randomized from 41 investigational sites (Appendix E2 in the online supplement), with the potential for the study to be stopped early for success or futility. Institutional review boards at each site approved the study, and all participants provided written informed consent (Appendix E1). Eligible participants were 40 years of age or older, met American Thoracic Society/European Respiratory Society Guidelines criteria for management of stable COPD, and were able to perform a 6-minute-walk test (6MWT) ≥140 m. Disease severity was assessed by HRCT. Participants were required to have ≥40% emphysema destruction in the target lobe (assessed at −920 Hounsfield units) and a ≥10% disease emphysema severity difference with the ipsilateral lobe. The target and ipsilateral lobes were required to be separated by an intact fissure, estimated visually to be ≥90% complete with no segmental vessels crossing between adjacent lobes (as assessed by the CT corelab; MedQIA). Eligible participants had severe dyspnea (Modified Medical Research Council scale \[mMRC\] ≥2); severe obstructive disease FEV~1~ ≤45% of predicted, after bronchodilators; and hyperinflation defined as TLC ≥100% and residual volume (RV) ≥150% of predicted. Participants agreed to attend required follow-up visits and maintain consistent nutrition and exercise habits during the study period (Appendix E3).

All subjects who had not completed a PR program in the prior 2 years were screened to determine if they should complete a PR program before entering the trial (Appendix E4). Baseline testing included pulmonary function, CT, and QoL assessments (Appendix E5). Randomization occurred within the electronic data capture system at a preprocedure visit (2:1 randomization to treatment or control group). Patients in both the treatment and control groups received optimal medical management throughout the study; the treatment group additionally received bronchoscopic SVS placement.

Procedure
---------

The SVS valve is designed for placement in selected regions of bronchial airways using a flexible bronchoscope, deployment catheter, and accompanying loader. The valve has a flexible umbrella that blocks inspired airflow to distal portions of lungs affected by disease, while allowing air and mucus to clear proximally from treated airways. Valves are removable using a flexible bronchoscope and forceps, if necessary. The valve comprises a frame made of a super-elastic, biocompatible alloy (Nitinol) and a polyurethane membrane ([Figure 1](#fig1){ref-type="fig"}). The membrane is held against the airway mucosa by six flexible struts, which expand and contract with airway movement during breathing. The valve is secured in position with five anchors and tips that gently penetrate the airway wall to a controlled depth.

![Key components of the Spiration Valve.](rccm.201902-0383OC_f1){#fig1}

An airway sizing system and calibrated balloon was used to determine the appropriate valve width size (5, 6, 7, and 9 mm \[the 9-mm valve was introduced after the initial 29 subjects had been randomized in the study\]) to treat target lobe airways ranging from 4.75 to 8.75 mm. The treatment algorithm called for the complete occlusion of one lobe; this was achieved by using one or more SVS valves to occlude all segments (i.e., lobar, segmental, and/or subsegmental airways). HRCT imaging and, if necessary, lung perfusion was used to select treatment lobes. Either upper or lower lobes could be targeted for treatment; the right middle lobe was not treated in this study. When two lobes both met criteria for emphysema and heterogeneity, the lobe with the lowest perfusion was treated. To limit subsequent adverse events, physicians were asked to follow a checklist to limit procedure duration. Treated patients remained in the hospital for at least 1 day. The total duration of post-procedural hospitalization was at the discretion of the local investigator and within the norms of clinical practice at the local center.

Outcome Measures
----------------

Follow-up and outcome assessments were scheduled for 2 weeks, 1, 3, and 6 months, and annually through 2 or 5 years for the control and treatment groups, respectively. The primary effectiveness endpoint was mean change in FEV~1~ post-bronchodilator from baseline to 6 months between treatment and control groups; 12-month results are also reported. Secondary effectiveness endpoints were FEV~1~ difference between responders, defined as a 15% or greater improvement; target lobe volume (TLV) reduction, only assessed in the SVS treatment group, measured by quantitative CT (QCT); hyperinflation, measured by the ratio of RV to TLC; health status and QoL, measured by St. George's Respiratory Questionnaire (SGRQ); dyspnea, measured by mMRC; and exercise capacity, measured by 6MWT. HRCT, plethysmography, and exercise assessments only occurred between baseline and 6 months; therefore, TLV, hyperinflation, and 6MWT data were not assessed at 12 months.

The primary safety endpoint was the incidence of prespecified composite thoracic serious adverse events (SAEs; Appendix E6) through 6 months; secondary safety endpoints were the rate of each category of thoracic SAEs and thoracic SAE rate per patient-year.

Statistical Analysis
--------------------

Analyses of SVS effectiveness and durability were conducted at 6 and 12 months, respectively. Using a Bayesian adaptive design ([@bib22], [@bib23]), two interim analyses of sample size adequacy were conducted when 100 and 160 participants were enrolled, at which time the predictive probability of eventual success was calculated. Based on these analyses, enrollment could be stopped early for futility or probable eventual success, whereas follow-up continued until the last subject reached 6 months. The maximum possible sample size was 220 (Appendix E7). Subjects with missing data were included in the analysis via Bayesian multiple imputation. The primary effectiveness objective (superiority of SVS based on FEV~1~ change from baseline to 6 mo) was considered statistically significant if the posterior probability (PP) exceeded 0.982, a prespecified threshold value chosen to control type I error rate (under simulation) of 0.025 or less.

Primary and secondary safety analyses were conducted by determining the 95% Bayesian credible intervals (BCIs) for the difference and ratio of composite SAE probabilities, as well as each individual thoracic SAE category, in the treatment and control groups (Appendix E8). Secondary effectiveness endpoints were computed as the difference between treatment and control groups at 6 and 12 months compared with baseline. Statistical analysis was conducted in the R statistical language (version 3.4.0; R Foundation for Statistical Computing).

Results
=======

The trial was conducted from October 8, 2013 to May 3, 2017 at 41 clinical sites (Appendix E1) with 172 participants ultimately randomized to treatment (*n* = 113, 65.7%) and control (*n* = 59, 34.3%) groups at 31 clinical sites ([Figure 2](#fig2){ref-type="fig"}). Enrollment was stopped when the predictive probability of success with the existing cohort was greater than 0.999. By 6 months in the treatment group, 6 subjects had died and 107 had an evaluable visit. By 12 months, 96 subjects had evaluable visits. In the control group (*n* = 59), 8 participants withdrew and 1 died, leaving 50 evaluable subjects at 6 months. By 12 months, 43 subjects had an evaluable visit.

![Study subject disposition flow chart.](rccm.201902-0383OC_f2){#fig2}

Treatment and control group participants had similar baseline characteristics. Demographic data, use of pulmonary medications and supplemental oxygen, medical history, lung function, arterial blood gas results, exercise tolerance, SGRQ, mMRC dyspnea scores, and HRCT characteristics were all comparable ([Table 1](#tbl1){ref-type="table"} and Appendix E9, Table E2). The only demographic difference was sex; the control group had approximately 15% more males.

###### 

Subject Demographics and Baseline Characteristics

                                 Treatment Group (*n* = *113*)   Control Group (*n* = *59*)                       
  ----------------------------- ------------------------------- ---------------------------- ---- --------------- -----------------
  Sex, M                                      113                        54 (47.8)            59     38 (64.4)     −30.9% to −0.8%
  Age, yr                                     113                        66.7 ± 6.6           59    68.1 ± 6.4       −3.4 to 0.7
  BMI, kg/m^2^                                113                        25.3 ± 4.3           59    24.6 ± 5.2       −0.8 to 2.3
                                                                                                                           
  FEV~1~, L                                   113                      0.825 ± 0.264          59   0.792 ± 0.260   −0.051 to 0.116
  FEV~1~% predicted                           113                        30.8 ± 8.1           59    28.5 ± 8.5       −0.4 to 5.0
  FVC, L                                      113                      2.492 ± 0.754          59   2.633 ± 0.757   −0.384 to 0.101
  FVC% predicted                              113                       70.2 ± 16.5           59    70.5 ± 16.7      −5.6 to 5.0
  TLC, L                                      113                      7.215 ± 1.530          59   7.649 ± 1.431   −0.904 to 0.035
  TLC% predicted                              113                       126.5 ± 14.5          59   128.2 ± 17.0      −6.9 to 3.5
  RV, L                                       113                      4.573 ± 1.253          59   4.848 ± 1.199   −0.665 to 0.115
  RV% predicted                               113                       207.5 ± 45.0          59   213.4 ± 49.3     −21.3 to 9.4
  RV/TLC ratio                                113                      0.632 ± 0.080          59   0.632 ± 0.086   −0.028 to 0.026
                                                                                                                           
  Prescribed O~2~                             113                                             59                           
   Proportion                                                            51 (45.1)                   27 (45.8)      −15.7 to 14.9
   L/min                                                                1.18 ± 1.43                 1.16 ± 1.47     −0.45 to 0.49
  P[o]{.smallcaps}~2~, mm Hg                  112                       67.9 ± 10.2           59    68.0 ± 11.6      −3.6 to 3.5
  P[co]{.smallcaps}~2~, mm Hg                 112                        40.2 ± 5.7           59    40.9 ± 6.0       −2.7 to 1.1
  Pulmonary rehabilitation                    113                                             59                           
   Before enrollment                                                     113 (100)                   59 (100)       −11.8 to 13.4
   During follow-up period                                               39 (34.5)                   18 (30.5)             
                                                                                                                           
  6MWT, m                                     113                       303.5 ± 84.6          59   306.9 ± 104.2    −34.8 to 28.0
  Dyspnea, mMRC                               113                        2.7 ± 0.7            59     2.7 ± 0.6       −0.2 to 0.2
  COPD assessment test                        113                        21.8 ± 6.8           59    20.0 ± 6.3       −0.3 to 3.9
  SGRQ total                                  113                       57.2 ± 14.8           59    54.6 ± 13.6      −1.9 to 7.1
                                                                                                                           
  TLV, L                                      113                      1.843 ± 0.602          59   1.820 ± 0.456   −0.140 to 0.187
  Target lobe                                 113                                             59                           
   Left lower                                                            27 (23.9)                   9 (15.3)      −4.2% to 19.5%
   Left upper                                                            66 (58.4)                   37 (62.7)     −17.8% to 12.0%
   Right lower                                                            7 (6.2)                    7 (11.9)      −15.9% to 2.8%
   Right upper                                                           13 (11.5)                   6 (10.2)      −9.4% to 10.1%
  Emphysema severity, %                       113                       63.6 ± 10.1           59    61.6 ± 11.6      −1.6 to 5.5
  Emphysema heterogeneity, %                  113                       25.3 ± 12.0           59    23.3 ± 11.6      −1.8 to 5.8

*Definition of abbreviations*: 6MWT = 6-minute-walk test; BCI = Bayesian credible interval; BMI = body mass index; C = control; COPD = chronic obstructive pulmonary disease; mMRC = Modified Medical Research Council; O~2~ = oxygen; RV = residual volume; SGRQ = St. George's Respiratory Questionnaire; T = treatment; TLV = target lobe volume.

Mean procedure duration, defined as the time between bronchoscope insertion and removal, was 24.3 minutes (range, 9--73 min). The mean and median duration of hospitalization was 3.83 days and 1 day, respectively (Appendix E10, Table E3). Target lobes, defined by preprocedural imaging, were primarily on the left side (82.3%), with 58.4% being the left upper lobe (Appendix E10, Table E4). QCT was used for target lobe selection in 97.4% of cases. In the remaining three cases, where two potential target lobes were identified by QCT, perfusion scan results were used, and final determination of the target lobe was by the CT corelab. A total of 476 valves were placed in 113 treatment group participants (mean number per participant, 3.83 ± 1.48; Appendix E10, Table E5).

Efficacy Outcomes
-----------------

The SVS treatment group had significant FEV~1~ improvements ([Figure 3](#fig3){ref-type="fig"}). At 6 months, the treatment group improved by 0.099 L on average from baseline (95% BCI, 0.069--0.128), whereas the control group changed by −0.002 L (95% BCI, −0.030 to 0.026), for a between-group difference of 0.101 L (95% BCI, 0.060--0.141). At 12 months, the treatment group improved by 0.067 L on average (95% BCI, 0.031 to 0.103), whereas the control group decreased by −0.032 L (95% BCI, −0.069 to 0.005), for a between-group difference of 0.099 L (95% BCI, 0.048--0.151). (Appendix E11, Table E6).

![Change in FEV~1~ at 6 and 12 months; data are shown as mean and 95% Bayesian credible interval (BCI). PP = posterior probability; SVS = Spiration Valve System.](rccm.201902-0383OC_f3){#fig3}

Secondary effectiveness outcomes were also improved in the SVS-treated group. At 6 and 12 months, the between-group difference in FEV~1~ responder rates (improvement, ≥15%) was estimated at 25.7% (95% BCI, 12.5%--37.5%; 0.9998 PP) and 30.4% (95% BCI, 16.8%--42.5%; 0.9999 PP), respectively, in favor of SVS ([Table 2](#tbl2){ref-type="table"} and Appendix E11, Tables E7--E9).

###### 

Responder Rates for All Effectiveness Outcomes

  Outcome Measure Responder Rates    Treatment Group \[*n/N (%)*\]   Control Group \[*n/N (%)*\]
  --------------------------------- ------------------------------- -----------------------------
  FEV~1~ (≥15% improvement)                                                        
   6 mo                                      39/106 (36.8)                   5/50 (10.0)
   12 mo                                     32/86 (37.2)                    2/39 (5.1)
  TLV (≥350 ml reduction)                                                          
   6 mo                                      76/102 (74.5)                       NA
  RV (≥310 ml reduction)                                                           
   6 mo                                      53/105 (50.5)                  16/50 (32.0)
  SGRQ (≥4 point reduction)                                                        
   6 mo                                      57/105 (54.3)                   9/50 (18.0)
   12 mo                                     48/95 (50.5)                    9/41 (22.0)
  mMRC (≥1 point reduction)                                                        
   6 mo                                      57/107 (53.3)                   9/50 (18.0)
   12 mo                                     46/94 (48.9)                    3/41 (7.3)
  6MWT (≥25 m improvement)                                                         
   6 mo                                      33/102 (32.4)                  11/48 (22.9)

*Definition of abbreviations*: 6MWT = 6-minute-walk test; mMRC = Modified Medical Research Council; NA = not applicable; RV = residual volume; SGRQ = St. George's Respiratory Questionnaire; TLV = target lobe volume.

At 6 months, treatment group participants had a significant reduction in TLV as measured by QCT (−0.974 L \[95% BCI, −1.119 to −0.829\]), with a 1.0000 PP for mean change less than 0 ([Table 3](#tbl3){ref-type="table"} and Appendix E11, Table E10). Using a 350-ml reduction in TLV as a threshold, 75% of the SVS-treated group achieved a clinically meaningful improvement, with 40% of the entire treatment cohort achieving complete atelectasis of the target lobe.

###### 

Secondary Effectiveness Outcomes

  Outcome Measure Described as Change from Baseline    Treatment Group \[*Mean* ± *SD (N)*\]   Control Group \[*Mean* ± *SD (N)*\]             Difference between Groups (*95% BCI*)             Posterior Probability of Superiority
  --------------------------------------------------- --------------------------------------- ------------------------------------- ----------------------------------------------------------- --------------------------------------
  TLV, L                                                                                                                                                                                                           
   6 mo                                                         −0.974 ± 0.74 (102)                            NA                    −0.974 (−1.12 to −0.83)[\*](#tblfn2){ref-type="table-fn"}                  1.0000
  RV, L                                                                                                                                                                                                            
   6 mo                                                         −0.402 ± 0.85 (105)                    −0.042 ± 0.58 (50)                             −0.361 (−0.59 to −0.13)                                   0.9990
  RV/TLC                                                                                                                                                                                                           
   6 mo                                                         −0.035 ± 0.08 (105)                     0.005 ± 0.04 (50)                             −0.039 (−0.06 to −0.02)                                   1.0000
  SGRQ                                                                                                                                                                                                             
   6 mo                                                          −8.1 ± 17.1 (105)                       4.8 ± 10.6 (50)                               −13.0 (−17.4 to −8.5)                                    1.0000
   12 mo                                                         −5.8 ± 16.8 (95)                        3.7 ± 10.9 (41)                               −9.5 (−14.4 to −4.7)                                     1.0000
  mMRC                                                                                                                                                                                                             
   6 mo                                                          −0.6 ± 1.0 (107)                        −0.0 ± 0.6 (50)                                −0.6 (−0.9 to −0.3)                                     1.0000
   12 mo                                                          −0.6 ± 1.1 (94)                        0.2 ± 0.6 (41)                                 −0.9 (−1.2 to −0.6)                                     1.0000
  6MWT, m                                                                                                                                                                                                          
   6 mo                                                          −4.4 ± 76.7 (102)                      −11.3 ± 51.4 (48)                               6.9 (−14.2 to 28.2)                                     0.7438

*Definition of abbreviations*: 6MWT = 6-minute-walk test; BCI = Bayesian credible interval; mMRC = modified Medical Research Council; NA = not applicable; RV = residual volume; SGRQ = St. George's Respiratory Questionnaire; TLV = target lobe volume.

Prespecified hierarchy of testing: TLV, hyperinflation (RV/TLC), SGRQ, dyspnea (mMRC), 6MWT, all at 6 months.

Compared with baseline.

The SVS treatment group also had significantly greater mean RV/TLC improvement. The between-group difference at 6 months was −0.039 (95% BCI, −0.058 to −0.020; 1.0000 PP) in favor of SVS ([Table 3](#tbl3){ref-type="table"} and Appendix E11, Table E11a).

There was significantly greater mean improvement in SGRQ (health status) for SVS treatment versus control groups at 6 months, with a between-group difference of −13.0 points (95% BCI, −17.4 to −8.5; 1.0000 PP). Results at 12 months were −9.5 points (95% BCI, −14.4 to −4.7; 1.0000 PP) ([Table 3](#tbl3){ref-type="table"} and Appendix E11, Table E12).

Dyspnea, as measured by mMRC, was significantly improved with SVS treatment, with a between-group difference of −0.6 (95% BCI, −0.9 to −0.3; 1.0000 PP) at 6 months and −0.9 (95% BCI, −1.2 to −0.6; 1.0000 PP) at 12 months ([Table 3](#tbl3){ref-type="table"} and Appendix E11, Table E13).

Although not a secondary endpoint of the study, the COPD assessment test scores were improved by 4.3 points at 6 months and 5.3 points at 12 months in the treatment group compared with the control group, and were statistically significant at both time points (Appendix E11, Table E16).

Change in exercise capacity, measured by 6MWT, was not statistically significant at 6 months, with a between-group difference of 6.9 m (95% BCI, −14.2 to 28.2; 0.7438 PP) ([Table 3](#tbl3){ref-type="table"} and Appendix E11, Table E14).

[Table 2](#tbl2){ref-type="table"} provides responder rates for all secondary efficacy outcomes.

Safety Outcomes
---------------

### Short term (0--6 mo)

At 6 months, the incidence of composite thoracic SAEs was 31.0% in the treatment group and 11.9% in the control group for a statistically significant between-group difference of 19.1% (95% BCI, 5.9--29.7). The higher treatment group incidence was primarily due to a 12.4% (95% BCI, 4.6--18.6) increased incidence of serious pneumothorax (Appendix E12, Tables E17 and E18), which was statistically significant. Over this time, 32 monitored events of pneumothorax were reported, with 18 protocol-defined (Appendix E6) serious incidents in 16 (14.2%) of 113 treatment group participants, and 14 nonserious pneumothorax events in 13 (11.5%) treatment group participants. The majority (66%) of these pneumothorax events occurred within 3 days of the procedure, within the average hospital stay duration (Appendix E12, Figure E1). Of the 16 subjects with serious pneumothorax events, 11 (69%) had one or more valves removed per the defined pneumothorax management protocol (Appendix E5). Five ([@bib5]) of these subjects had valves reimplanted upon cessation of the pneumothorax, and this subset showed a TLV reduction of −834.0 ml compared with only −19.2 ml in those that did not have valves replaced. There were no other statistically significant between-group differences in thoracic SAEs by category.

There were six (5.3%) deaths in the treatment group and one (1.7%) death in the control group (Appendix E12, Table E19). This difference between groups was not statistically significant. Only one death (occurring at Day 95 after SVS procedure) was adjudicated by the study clinical events committee as possibly related to the device due to pneumothorax in the contralateral untreated lobe, which did not resolve before death (Table E20).

There were no statistically significant between-group differences for non-horacic SAEs, with 11.5% and 3.4% nonthoracic SAEs in the treatment and control groups, respectively (Appendix E12, Table E19).

### Long term (6--12 mo)

Between 6 and 12 months, the incidence of composite thoracic SAEs was 21.4% in the treatment group versus 10.6% in the control group (Appendix E12, Table E17), with a between-group difference of 10.7% (95% BCI, −3.0 to 21.2), which was not statistically significant. There were no statistically significant between-group differences in thoracic SAEs by category. There were 3 nonserious events of pneumothorax in 2 of 113 (1.7%) treatment subjects, and no additional serious pneumothorax events (Appendix E12, Figure E1). Three SAEs were adjudicated as device related (one case of infection, one of pneumonia, and one death). There were four (3.9%) deaths in the treatment group (one of which was device related) and three (6.4%) in the control group (Appendix E12, Tables E17 and S19; death details in Table E21). There were no unanticipated device-related SAEs or migration, erosion, or expectoration reported through 12 months of follow-up.

There were no statistically significant between-group differences for nonthoracic SAEs, with rates of 12.6% and 12.8% in the treatment and control groups, respectively (Appendix E12, Table E19).

Discussion
==========

The EMPROVE trial evaluated the safety and efficacy of the SVS compared with optimal medical management in patients with severe heterogeneous emphysema. Although prior SVS trials using bilateral, partial occlusion of the target lobe did not show consistent improvement ([@bib10], [@bib11]), the results of the EMPROVE trial, with single-lobe, total lobar occlusion, shows marked benefits. At 6 months, the primary outcome and a majority of secondary outcome measures were improved in the SVS treatment group compared with the control group. There was a significant between-group increase in mean FEV~1~ from baseline (0.101 L) and a 25.7% between-group difference in FEV~1~ responder rates (defined as improvement of ≥15%). These results persisted at 12 months. The SVS treatment group also saw significant reductions in TLV, hyperinflation, and dyspnea. Improved health status and QoL was observed as an 8.1-point mean reduction in the SGRQ, which exceeds the 4-point minimum score change defined as clinically relevant ([@bib24]). These efficacy results are very comparable to other randomized clinical trials using one-way valves in a unilateral lobar treatment paradigm ([@bib13], [@bib14], [@bib16], [@bib25]).

Although the SVS treatment group performed better on the 6MWT than the control group (between-group difference, 6.9 m), this difference was not statistically significant. In contrast, patients who underwent endobronchial valve treatment in the recent LIBERATE (Lung Function Improvement after Bronchoscopic Lung Volume Reduction with Pulmonx Endobronchial Valves Used in Treatment of Emphysema) trial performed significantly better on 6MWT than control subjects. This improvement is not surprising, as LIBERATE patients were required to maintain a supervised PR program throughout study follow-up ([@bib25]), and PR has been shown to improve exercise capacity in patients with COPD ([@bib26]). The EMPROVE study was designed with the understanding that only ∼40% of patients with COPD actually adhere to a PR program due to problems with access and prohibitive cost ([@bib27]). As such, EMPROVE subjects were required to have been in a PR program in the 2 years before study enrollment (Appendix E4), but were not mandated to maintain a supervised PR program throughout the study follow-up, with only 34.5% and 32.7% of EMPROVE treatment and control subjects, respectively, maintaining a PR regimen through the 12-month follow-up. Thus, the difference between the two trials highlights the importance of additional exercise training by way of PR in translating improved lung function into enhanced exercise performance.

Mean procedure time in EMPROVE (24 min) was also shorter than that observed in the LIBERATE trial (34 min) ([@bib25]). This is relevant because shorter procedure times have been associated with fewer procedure-related complications ([@bib11]). In the EMPROVE study, post-SVS treatment risks were generally minor and tended to diminish over time. The primary safety outcome, incidence of composite thoracic SAEs, was greater in the treatment than in the control group (31.0% and 11.9%, respectively). However, pneumothorax was the only individual SAEs with significantly higher treatment group incidence, similar to comparable studies ([@bib13], [@bib25]). Early-onset pneumothorax in the treatment group likely resulted from lung conformation changes due to acute reduction in lung volume by valve therapy, triggering rapid ipsilateral nontargeted lobe expansion, a recognized indicator of successful target lobe occlusion ([@bib28]). There was no statistically significant difference in mortality between the study groups at any time point. The 5.3% mortality rate in the treatment group is similar to the 3.1--5.0% documented in other randomized valve trials ([@bib11], [@bib25], [@bib29], [@bib30], [@bib31]), and lower than the 7.9--12% documented in randomized LVRS trials ([@bib7]). There were no unanticipated device-related SAEs.

The results of the EMPROVE trial also demonstrate that using HRCT analysis for fissure integrity ≥90% is a useful method to select patients for lack of collateral ventilation that are most likely to achieve targeted lobe atelectasis and improved clinical outcomes. The procedural time for SVS performance was less than other trials using physiological assessment for collateral ventilation, and avoids added procedural costs ([@bib32], [@bib33]). Moreover, in a broader clinical context, HRCT quantitative assessment of fissure integrity may be easier to implement.

Strengths and Limitations
-------------------------

Strengths of the EMPROVE trial include its use of an adaptive sample size, thus shortening overall enrollment time, and planned long-term follow-up: 5 and 2 years for the treatment and control groups, respectively. A key study limitation was the lack of TLV and hyperinflation assessments at 12 months, which would have provided mechanistic data to support improvements in functional and QoL parameters. In addition, the EMPROVE study, and other recent multicenter, randomized controlled trials, did not blind either subjects or assessors ([@bib16], [@bib25], [@bib34]). Although this may introduce bias to the QoL assessments and the 6MWT, it is unlikely that measures such as lung function, TLV, and hyperinflation would be affected by this approach.

Conclusions
-----------

Treatment of severe heterogeneous emphysema with the SVS in medically optimized participants selected for fissure integrity ≥90% by quantitative HRCT achieved significant improvements in FEV~1~, hyperinflation, TLV, dyspnea, and QoL measures compared with optimal medical management alone. The SVS offers clinically relevant benefits for severely ill patients with emphysema and, although there are risks with the therapy, they are primarily manageable and tend to diminish over time.

The results of the EMPROVE trial and other randomized trials of valve therapy have led to the inclusion of endobronchial valve therapy as an important component of the clinical therapy recommendations for the underserved patient population with severe emphysema ([@bib35], [@bib36]).
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